interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Cedazuridine; Decitabine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Cedazuridine; Decitabine, and who makes it?

Cedazuridine; Decitabine appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Cedazuridine; Decitabine1 dosage-form group in the Orange Book
0generic makers listed
  1. Cedazuridine; Decitabine appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Inqovi. No generic is listed as marketed.

20202025203020352040204501brand 2020data datePatent 8618075 listed to expire 16 October 2028Patent 9567363 listed to expire 16 October 2028Patent 8268800 listed to expire 12 February 2034Patent 12195496 listed to expire 7 October 2040Patent 12239653 listed to expire 24 February 2041Patent 11963971 listed to expire 24 February 2041Patent 12697347 listed to expire 10 December 2042Exclusivity ODE-316 to 7 July 2027Exclusivity I-990 to 13 May 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 July 2027Exclusivity ODE-316 Inqovi
  • 13 May 2029Exclusivity I-990 Inqovi
  • 16 October 2028Patent 8618075
  • 16 October 2028Patent 9567363 drug substance
  • 12 February 2034Patent 8268800 drug substance
  • 7 October 2040Patent 12195496 drug product
  • 24 February 2041Patent 12239653
  • 24 February 2041Patent 11963971 drug product
  • 10 December 2042Patent 12697347

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.